Zobrazeno 1 - 10
of 2 038
pro vyhledávání: '"A, Aprikian"'
Autor:
M. Eric Hyndman, Robert J. Paproski, Adam Kinnaird, Adrian Fairey, Leonard Marks, Christian P. Pavlovich, Sean A. Fletcher, Roman Zachoval, Vanda Adamcova, Jiri Stejskal, Armen Aprikian, Christopher J. D. Wallis, Desmond Pink, Catalina Vasquez, Perrin H. Beatty, John D. Lewis
Publikováno v:
npj Digital Medicine, Vol 7, Iss 1, Pp 1-11 (2024)
Abstract The current prostate cancer (PCa) screen test, prostate-specific antigen (PSA), has a high sensitivity for PCa but low specificity for high-risk, clinically significant PCa (csPCa), resulting in overdiagnosis and overtreatment of non-csPCa.
Externí odkaz:
https://doaj.org/article/32101f2e4bdf41bc810afa318fa28979
Autor:
Wissing, Michel, Brimo, Fadi, McKercher, Ginette, Scarlata, Eleonora, Saad, Fred, Carmel, Michel, Lacombe, Louis, Têtu, Bernard, Ekindi-Ndongo, Nadia, Latour, Mathieu, Trudel, Dominique, Chevalier, Simone, Aprikian, Armen
Publikováno v:
In Human Pathology April 2024 146:66-74
Autor:
Adrian Fairey, Robert J. Paproski, Desmond Pink, Deborah L. Sosnowski, Catalina Vasquez, Bryan Donnelly, Eric Hyndman, Armen Aprikian, Adam Kinnaird, Perrin H. Beatty, John D. Lewis
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 15797-15808 (2023)
Abstract Background There is an unmet clinical need for minimally invasive diagnostic tests to improve the detection of grade group (GG) ≥3 prostate cancer relative to prostate antigen‐specific risk calculators. We determined the accuracy of the
Externí odkaz:
https://doaj.org/article/7cc21a9c19b34b639acb32d08cca5624
Autor:
Michel D. Wissing, Ana O’Flaherty, Alice Dragomir, Simon Tanguay, Wassim Kassouf, Armen G. Aprikian
Publikováno v:
BMC Urology, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Studies have suggested a positive association between bladder cancer (BC) outcome and comedication use, including nonsteroidal anti-inflammatory drugs (NSAID), metformin, and prednisone use. To validate these associations, we eval
Externí odkaz:
https://doaj.org/article/587dd4100c534cd0a058880266c10eda
Autor:
Seta Derderian, Tarik Benidir, Eleonora Scarlata, Turki Altaylouni, Lucie Hamel, Fatima Zahra Zouanat, Fadi Brimo, Armen Aprikian, Simone Chevalier
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 9, Iss 4, Pp 285-301 (2023)
Abstract The androgen receptor (AR) plays a crucial role in the development and homeostasis of the prostate and is a key therapeutic target in prostate cancer (PCa). The gold standard therapy for advanced PCa is androgen deprivation therapy (ADT), wh
Externí odkaz:
https://doaj.org/article/3b080a72a7ea4ce8b3b1e57dc0f2de77
Publikováno v:
Cancer Medicine, Vol 13, Iss 3, Pp n/a-n/a (2024)
Abstract Background Prostate cancer (PCa) patients receiving radiotherapy may be predisposed to secondary malignancies. This study aimed to determine the association between PCa treatments, including radical prostatectomy (RP), external beam radiatio
Externí odkaz:
https://doaj.org/article/b1b706c1b3034fefbe1d0940137bc7b1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Bárcena, Patricia Grisel Quintana1,2 (AUTHOR), Aprikian, Armen Garo1,3 (AUTHOR), Dragomir, Alice1,2,4 (AUTHOR) alice.dragomir@umontreal.ca
Publikováno v:
Cancer Medicine. Feb2024, Vol. 13 Issue 3, p1-12. 12p.
Autor:
Lacombe, Louis, Hovington, Hélène, Brisson, Hervé, Mehdi, Sadia, Beillevaire, Déborah, Émond, Jean-Philippe, Wagner, Antoine, Villeneuve, Lyne, Simonyan, David, Ouellet, Véronique, Barrès, Véronique, Latour, Mathieu, Aprikian, Armen, Bergeron, Alain, Castonguay, Vincent, Couture, Félix, Chevalier, Simone, Brimo, Fadi, Fazli, Ladan, Fleshner, Neil, Gleave, Martin, Karakiewicz, Pierre I., Lattouf, Jean-Baptiste, Trudel, Dominique, van der Kwast, Theodorus, Mes-Masson, Anne-Marie, Pouliot, Frédéric, Fradet, Yves, Audet-Walsh, Etienne, Saad, Fred, Guillemette, Chantal, Lévesque, Eric
Publikováno v:
In Cancer Letters 28 January 2023 553
Publikováno v:
Current Oncology, Vol 29, Iss 11, Pp 8626-8637 (2022)
Background: The introduction of novel hormonal agents (NHAs) such as abiraterone acetate (ABI) and enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) was an important milestone given their survival benefits, tolerability,
Externí odkaz:
https://doaj.org/article/b5cc9a3fa2f74765826e3fb78f0efa5b